European Council Move Brings SPC Manufacturing Waiver A Step Closer
Executive Summary
A proposed SPC manufacturing waiver – which would allow generic and biosimilar manufacturing within Europe during the SPC period – has taken a step closer to being realized after the European Council approved a mandate for negotiations with the European Parliament. However, it remains uncertain whether key elements desired by the off-patent industry will fall into place.
You may also be interested in...
BIA ‘Reassured’ On Post-Brexit SPC Regime But Data Exclusivity Concerns Remain
The government has said it is prepared to discuss the terms of supplementary protection certificates under a UK-only regime if there is a no-deal Brexit, but concerns also linger over the start dates for regulatory data protection.
Beefed-Up SPC Manufacturing Waiver Gains Traction In European Parliament
A proposal to allow generics firms to manufacture versions of supplementary protection certificate-protected medicines in preparation for EU launch immediately on SPC expiry is making progress through the European parliamentary process, to the delight of the generics industry – and the dismay of originator companies.
SPC Waiver Builds Momentum After EU Vote
Several EU-level endorsements for a proposed SPC manufacturing waiver – which would allow manufacturing within Europe during the SPC period for export, as well as stockpiling for ‘day one’ launch upon SPC expiry – have been applauded by the region’s off-patent industry. However, originators are doubling down on lobbying efforts against such changes.